ArticleFrontiers in nutrition2026
Metabolomic dysregulation in the association between major depressive disorder and chronic pancreatitis: a large prospective cohort study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) is increasingly recognized as a systemic condition accompanied by metabolic disturbances, particularly in lipid metabolism. However, whether MDD is associated with the development of chronic pancreatitis (CP), a chronic inflammatory disease with substantial metabolic and nutritional consequences, remains unclear. We aimed to investigate the prospective association between MDD and incident CP and to assess the potential mediating role of circulating nuclear magnetic resonance (NMR)-based metabolic biomarkers. Methods: In this prospective study of 273,524 UK Biobank participants, MDD was identified using hospital records and self-reports. Incident CP was ascertained through linked health records. Cox proportional hazards models were used to estimate associations, and mediation analyses based on NMR metabolomics were performed. A metabolomic signature was further derived using least absolute shrinkage and selection operator (LASSO) regression. Results: Over a median follow-up of 13.7 years, 411 incident CP cases were identified. MDD was independently associated with an increased risk of CP (HR 1.47, 95% CI 1.10-1.96). Exploratory mediation analyses suggested that lipid-related metabolites accounted for part of the observed association, including triglycerides in HDL particles (HDL-TG; 5.10%), triglycerides in LDL particles (LDL-TG; 4.19%), and fatty acid unsaturation (7.61%). A 51-metabolite signature explained 20.80% (95% CI 13.20-27.20%) of the association. The association was stronger in participants aged ≤60 years ( Conclusion: Major depressive disorder was associated with a higher risk of CP, and exploratory mediation analyses suggested that lipid related metabolomic alterations may account for part of this association. These findings highlight metabolic dysregulation as a potential biological correlate of the observed MDD-CP association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.